Materials for the 2nd Extraordinary General Meeting in 2026
Filed with SSE · · 10 pages · Chinese
On 6ix: 6ix.com/news/dizal-pharmaceutical-co-ltdmaterials-for-the-2nd-extraordinary-general-meeting-in-2026
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Announcement on Abnormal Fluctuations in Stock Trading
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Voluntary Disclosure of Multiple Latest Research Advances in Lung Cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
- Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
Later from Dizal (Jiangsu) Pharmaceutical
- Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Providing Guarantee for Controlled Subsidiary
- Announcement on Resolutions of the 1st Meeting of the 3rd Board of Directors
- Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical